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1. Introduction 
In developing mammals (including humans), a deficiency or excess of thyroid hormone 
(TH) in the developing brain during the fetal and neonatal periods can lead to 
morphological and functional abnormalities (Nunez et al., 1992; Pasquini & Adamo, 1994; 
Morreale de Escobar et al., 2004; Harakawa et al., 1989). The most severe form of 
hypothyroidism in human fetus and neonate is the syndrome of cretinism. Recent studies 
indicate that abnormalities in intelligence quotient (IQ) and other neuropsychological tests 
may be found in children of women with subclinical hypothyroidism during pregnancy 
(Haddow et al., 1999; Mitchell & Klein, 2004; Casey et al., 2005). Subtle health impairment 
and reduced socio-educational achievement are observed in young adults with congenital 
hypothyroidism identified by neonatal screening and subsequently treated (Leger et al., 
2011). This suggests the inadequacy in the current strategy with neonatal screening – it may 
already be too late to secure normal neurological development. Studies of populations 
indicate that congenital hypothyroidism affects 1 in 3,000 to 4,000 newborns; twice as many 
females as males. A recent report showed that the incidence in the United States increased 
from ~ 1:4100 in 1987 to ~ 1:2400 in 2002 (Rastogi & LaFranchi, 2010; Harris & Pass, 2007). 
The causes for this change are not entirely clear even though the screening strategy may 
have contributed to the increase (Rastogi & LaFranchi, 2010). 
2. Etiology of congenital hypothyroidism  
Most cases of congenital hypothyroidism are sporadic. But an estimated 15 to 20 percent of 
cases are inherited including mutations in the DUOX2, PAX8, SLC5A5(NIS), SLC26A4(PDS), 
TG, TPO, DEHAL1, TSHB, and TSHR genes (Table 1; Rastogi & LaFranchi, 2010; Grasberger 
& Refetoff, 2011). Many inherited cases are autosomal recessive but those with a mutation in 
the PAX8 gene or certain TSHR gene mutations have an autosomal dominant pattern of 
inheritance. Another possible cause of fetal hypothyroidism is anti-thyroid medication 
treatment for maternal hyperthyroidism during pregnancy (Rastogi & LaFranchi, 2010; 
Rovet et al., 1999; Mirabella et al., 2000; Vanmiddlesworth et al., 2011). In severe iodine-
deficient regions, the prevalence of cretinism can reach 10% of the local population; WHO 
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estimates indicate a prevalence in the millions worldwide (World Health Organization 
[WHO], 2004; WHO et al., 2007).  
 
Category Etiology Mechanism  Note 
Thyroid Failure Developmental 
Anomaly 
Dysgenesis 98% unknown; others 
associated genetic 
mutation: TTF, NKX2.1, 
NKX2.5, PAX-8 
 Impaired production Mutations on TH 
synthesis 
NIS**, Peroxidase 
(DUOX2, DUOXA2), 
Pendred syndrome, Tg,  
Iodotyrosine deiodinase 
(DEHAL1, SECISBP2) 
 TSH Binding Receptor defect  
 TSH Signaling G-protein   
Secondary 
Hypothyroidism 
TSH Recetor TSH β  
 TRH Synthetic defect PSIS**, Hypothalamic 
lesion 
  Resistance Receptor mutation 
 Pituitary 
development/ 
function  
Deficient 
transcription 
factors 
HESX1, LHX3, LhX4, PIT1, 
PROP1 gene mutations 
Peripheral Tissue TH resistance TSH β  
 Transporter Abnormal TH 
transporter 
MCT8 mutation 
Transient Antithyroid 
medication 
Maternal 
Hyperthyroidism 
 
 Antibodies Autoimmune TSHR blocking antibody 
 Iodine Excess or 
deficient 
Endemic goiter, a major 
world health problem 
 Hepatic 
Hemangioma 
Excess TH 
degradation 
Type III deiodinase 
Associate with 
other 
Abnormalities 
Cleft palate  TTF-2 mutation 
 Respiratory distress, 
Benign Chorea  
Choreoathetosis NKX2.1/TTF-1 mutation 
** NIS: Sodium-iodide symporter; ** PSIS: pituitary stalk interruption syndrome 
Table 1. Causes of Congenital Hypothyroidism 
Concerns regarding fetal hypothyroidism and timely treatment warrant close monitoring of 
fetal thyroid status. One method, cordocentesis, is invasive and has a fetal loss rate of 0.5 to 
1% (Daffos, 1989). Recently, ultrasonography has been utilized to assess the fetal thyroid 
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gland (Harris & Pass, 2007; Polak & Van Vliet, 2010; Luton et al., 2005; Abuhamad et al., 
1995; Ribault et al., 2009). Cordocentesis and serial ultrasonographic measurements are 
either invasive or laborious. The development of a convenient non-invasive means to 
monitor fetal thyroid function is definitely needed.  
3. Alternate pathways of Iodothyronines 
The alternate pathways of thyroid hormone metabolism include conjugation (sulfation or 
sulfonation, and glucuronidation of the phenolic hydroxy group) and, to a lesser extent, 
oxidative deamination of the alanine side-chain leading to the formation of the 
corresponding iodothyroacetates and ether link cleavage (Fig. 1; Wu et al., 2005).  
 
Fig. 1. Alternate pathways of thyroid hormone metabolism. The alternate pathways of 
thyroid hormone metabolism include conjugation (sulfation or sulfonation, and 
glucuronidation) and oxidative deamination of the alanine side-chain leading to the 
formation of the corresponding iodothyroacetates and ether link cleavage. DIT: 
diiodotyrosine; tetrac: tetraiodothyroacetic acid; tetram: tetraiodothyronamine. 
Alternate pathways may serve as mechanisms for further regulation of the bioavailabilities 
of thyroid hormones in tissues, in addition to deiodination in various physiological and 
pathophysiological states. Sulfoconjugation of iodothyronines, for example, is an important 
pathway in developing mammals (Wu et al., 2005); and sulfated iodothyronines can also be 
deiodinated, even at a faster rate. Likewise, iodothyroacetates can be sulfated and further 
deiodinated. Iodothyronine glucuronides are rapidly excreted in the bile. Furthermore, 
sulfoconjugation and glucuronidation are not irreversible pathways for thyroid hormone 
metabolism. Glucuronides can be hydrolyzed in the intestine and reabsorbed, and 
sulfoconjugates can be desulfated in selective tissues, e.g. liver and brain, and become 
available to nuclear receptors, especially in fetuses where type I deiodinase (D1) activity is 
low. The in vivo occurrence of the decarboxylated metabolites of T4 and T3, 3,3’,5,5’-
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tetraiodothyronamine (T4AM), and 3,3’5-triiodothyronamine (T3AM) have not been 
demonstrated (Leonard & Kohrle, 2000). However, recently, 3-monoiodothyronamine (3-
monoam or 3-T1AM) and thyronamine (T0AM) have been identified in brain and other 
tissues in rodents (Scanlan et al., 2004); monoam was found to have rapid effect on reducing 
rectal temperature in mice and is a potent agonist of the G protein-coupled trace amine 
receptor TAR1 (Scanlan, 2009). A single dose of T1AM administered to rodents induces a 
hypometabolic state that in certain ways resembles hibernation. Monoam may be derived 
from low iodinated iodothyronines by aromatic amino acid decarboxylase (Fig. 1 & 2), 
however, its role in developing mammals is not known. 
 
Fig. 2. Postulated T1 AM (monoam) formation. T4AM is not a substrate for type I or II 
deiodinase (D1 or D2) and cannot be deiodinated to T3AM. However, T4AM is readily 
deiodinated to rT3AM by D3, and rT3AM can be further deiodinated to ultimately provide 
T1AM. This suggests a unique biosynthetic deiodination pathway for T1AM starting from 
the decarboxylation products of either T4 or rT3. 
4. Sulfoconjugation of Iodothyronines 
Sulfoconjuation has been found to be a major pathway for thyroid hormone metabolism in 
mammalian fetuses (Fig. 1; Burrow et al., 1994; Wu et al., 2005; Simpson et al., 2005). The 
sulfation of thyroxine (T4) and triiodothyronine (T3) and their metabolites [reverse T3 (rT3) 
and 3,3’- diiodothyronine (T2)] may accelerate their further degradation and excretion. The 
sulfation of T4 completely blocks the outer-ring deiodination to T3S. In addition, sulfated 
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iodothyronines may serve as a reservoir for biologically active hormones such as T3, which 
can be recovered from T3S by sulfatases in selective tissues (Wu et al., 2005).  
By far, T2 is the preferred substrate for various mammalian sulfotransferases (SULTs). The 
purpose of rapid sulfation of T2, as well as rT3 in some tissues studied, is unknown. It is 
interesting that T2 has been found to stimulate mitochondrial respiration in various rat 
tissues (Moreno et al., 1997) and rT3 may play a role in regulating actin polymerization in 
brain cells (Leonard & Farwell, 1997). Also, sulfated T2 is the preferred substrate for both 
human and rat arylsulfatase (ARS) in the microsomal fraction of liver and placenta (Wu et 
al., 2005). Thus, the possibility that these T4 metabolites may play a physiological role in 
developing animals cannot be excluded.  
5. Sulfoconjugation of Iodothyronines and their placental transfer in sheep 
Before the onset of active synthesis and release of TH, iodothyronines detected in the fetus 
clearly are maternal in origin. This period is approximately the first 17 gestational days (d) 
in rats, 50d in sheep (Fig. 3) and 90d in humans.  
 
Fig. 3. Postulated metabolic pathways for ovine fetal thyroid hormones. D1, D2, and D3: 
type I, type II, and type III iodothyronine deiodinases; ST: iodothyronine sulfotransferases 
(SULT). LAO/AT: L-amino acid oxidase/aminotransferase; DiacS: sulfated 3,3’-
diiodothyroacetic acid. Heavy solid lines indicate pathways that are more active in fetuses 
than in adults; thin solid lines, pathways that are less active in fetuses. The upper horizontal 
light dotted line depicts T4 of maternal origin moving to the fetal compartment in the first 
trimester, before the fetal thyroid begins functioning. Other broken lines represent 
unconfirmed pathways. Numbers in parentheses indicate published production rates 
(µg/kg/d). 
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The proposed scheme for ovine fetal iodothyronine metabolism in late gestation (near term) 
depicts the production rates for sulfoconjugated thyroid hormone analogs (shown as numbers 
in parentheses along the thick arrows in Fig. 3). The high production rate (ug/kg/d) of T4 
sulfate (T4S) reflects the activity of the sulfation pathway. The rT3S production rate likely 
represents both sulfation of rT3 and inner-ring deiodination of T4S. This scheme shown in Fig. 3 
also predicts 3,3’-T2S is a major thyroid hormone metabolite in the fetus.  
The transfer of TH and their metabolites may be a two-way street. We have shown high 
concentrations of sulfated iodothyronine analogs in human and ovine fetal serum. These 
include T4S, T3S, rT3S, and 3,3’-T2S (T2S) (Wu et al., 2005). The high gradient between fetal 
and maternal serum concentrations of iodothyronine sulfates raises the possibility that there 
may be significant fetal to maternal transfer of iodothyronine sulfoconjugates. When the 
ovine fetus was infused with pharmacological amounts (0.46 µmoles) of T3 or T3S, significant 
fetal to maternal transfer of T2S and T3S occurred (Wu et al., 1995; Wu et al., 1999; Wu et al., 
2006). It is noteworthy that significantly more T3S than T2S of fetal origin was recovered in 
maternal urine following the fetal infusion of either T3 or T3S.  
Furthermore, maternal T2S and T3S levels were significantly higher after fetal T3 than after 
T3S infusion despite the fact that the mean fetal serum concentration of T3S after fetal T3S 
infusion was 20 times higher than following T3 infusion (Wu et al., 1995). On the other hand, 
after fetal infusion of 125I-T3, without disturbing the fetal stable T3 pool, a mean of 19% of 
infused radioactive dose was recovered in maternal urine in 4 h. T2S, not T3S, was identified 
as the major radioactive iodothyronine in fetal to maternal transfer; only minimal amounts 
of T3S or T3, were found (Wu et al., 2006).  
We also assessed the contribution of fetal TH to the urinary T2S and T3S pool in ewes. Maternal 
urinary T2S excretion (pmol/g creatinine) is significantly reduced by fetal thyroidectomy (Tx) 
but not by maternal Tx (Wu et al., 2001). Maternal urinary T2S excretion correlated positively 
with fetal serum T4 concentrations but not with maternal serum T3 or T4 levels (Wu et al., 2001). 
In view of a possible functional role of T2 to stimulate mitochondrial respiration, the removal 
of T2 from fetal compartment may be necessary for normal maturation of mammalian fetuses 
(Wu et al., 2005). Furthermore, recent study showed that ARSC, the only sulfatase that 
hydrolyzes iodothyronine sulfates, has a substrate preference for T2 (Kester et al., 2002), which 
raises the possibility that T2S could be readily reversed back to its precursor, an active 
iodothyronine. This would suggest a need for the fetus to remove T2S from fetal compartment. 
Furthermore, in the sheep model, T2S of fetal origin contributes significantly to maternal 
urinary T2S excretion and may reflect fetal iodothyronine production. 
6. The Evaluation a T2S-crossreactive material (compound w) as a potential 
marker for fetal thyroid function 
In humans, we found high levels of radioimmunoassayable T2S in maternal serum (Wu et 
al., 1994) and urine (Wu et al., 1998). Levels increased with the progression of pregnancy 
and peaked before parturition. At delivery, a 20-fold increase in serum “T2S” was found 
compared to non-pregnant women and “T2S” levels returned to non-pregnant values in 7 to 
10 days (Fig. 4 & 5). On closer examination, the radioimmunoassayable “T2S” did not 
cochromatograph with synthetic T2S by HPLC (Wu et al., 1994). The authentic T2S was 
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hydrolyzed by hot-acid digestion (Wu et al., 1994). Using this procedure, the recovery of 
T2S-crossreactive material was near 82% in fetal and maternal serum (Fig. 6; Wu et al., 2007).  
 
Fig. 4. Change of serum concentrations of compound W in cord and maternal serum. 
Compound W, expressed as ng/dl of T2S, in newborns and maternal serum samples at the 
time of delivery (D). The connected lines represent serial measurements in the same patients (n 
= 18). T2S concentrations also were measured in 14 nonpregnant women (NP) for comparison. 
The decrease in serum compound W concentrations after parturition is depicted in the semilog 
plot in the inset. The closed circles and vertical bars represent the mean ± SEM and (n) 
represents the total number of samples studied at each time period in a total of 35 patients. 
 
Fig. 5. Changes of compound W at different gestation periods. Normal values of T2S-
crossreactive material (compound W) in serum from pregnant women, nonpregnant women 
(NP), and newborns. Vertical bars are mean ± 1 SD. * p < 0.05 cf. 3-7 weeks pregnancy. 
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Fig. 6. Recovery of T2S-crossreactive material following hot-acid treatment. Top: Percent of 
T2S-crossreactive fraction that is hot-acid stable in cord (n = 6) and maternal (n = 12) serum 
samples.  
The maternal and paired cord serum concentrations of T2S-reactive material presented were 
adjusted by this percentage to obtain the hot-acid-resistant T2S-equivalent activity, or the 
“corrected” value. Over 40 known synthetic thyroid hormone analogs were examined and 
none was found to be identical to the T2S-like material in pregnant women’s serum. Thus, 
the name Compound W was given. It is postulated that W is a side-chain modification of 
T2S, which cross-reacts with T2S antibody but is slightly more hydrophobic than T2S. A 
possible candidate is N, N-dimethylated T2S (Fig. 7; Wu et al., 2007).  
To explore the possible origin of compound W, the serum concentrations of sulfated 
iodothyronines from cord arterial and venous samples were compared. There were no 
significant differences between the mean T3S, T4S, or rT3S concentrations of arterial and 
venous serum samples. However, the venous T2S-equivalent concentration was higher than 
arterial in seven of the paired samples and lower in two. The mean “corrected” W 
concentration in paired arterial/venous cord serum was found to be significantly higher in 
venous samples than in arterial samples (Wu et al., 2007). In addition, the mean of the 
maternal serum concentrations of T2S-reactive material was significantly lower than that of 
the paired cord serum concentrations. The rapid disappearance of W from maternal serum 
immediately after delivery supports this hypothesis (Wu et al., 1994). A similar 
disappearance slope of serum W was also found in newborn infants (Chen et al., 2010). 
These findings support the postulation that W is produced in the placenta. 
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Fig. 7. Postulated pathway converting T2S to N, N-methyl- T2S. N, N-methyl- T2S has the 
same physico-chemical characteristics on HPLC and reaction to T2S-specific antibody.  
 
Fig. 8. Levels of T2S-crossreactive material in paired maternal and cord serum at term. The 
solid line is the trend-line from lineal regression analysis for the correlation 
(n = 436, R = 0.686).  
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Prior studies suggest strongly that compound W is a metabolite of fetal thyroid hormone 
capable of transplacental fetal to maternal transfer (Wu et al., 2005; Wu et al., 1994; 
Cortelazzi et al., 1999; Wu et al., 2007). Both maternal and fetal compound W levels increase 
progressively during gestation with significant direct correlation (in both mothers and 
fetuses). Additionally, in 436 paired cord and maternal sera obtained at delivery, a highly 
significant positive correlation was observed between fetal and maternal compound W (Fig. 
8). A significant positive correlation was also observed between serum levels of fetal 
compound W and fetal FT4 and between maternal and fetal compound W (Fig. 9; Cortelazzi 
  
Fig. 9. Compound W levels in fetal serum: correlation with serum fetal FT4 (n=29) and 
maternal compound W (n=42). [Cortelazzi et al., 1999, reproduced with permission from 
European J. Endocrinology] 
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et al., 1999) whereas no correlation was observed between maternal serum compound W 
and maternal serum FT4 in euthyroid or hyperthyroid women. Furthermore, maternal 
compound W levels seem to reflect the effects of drugs on fetal thyroid function (Cortelazzi 
et al., 1999). In women on propylthiouracil (PTU), maternal compound W levels were in the 
low normal range and did not show the usual increase with progression of gestation 
(Cortelazzi et al., 1999). The lack of progression in maternal compound W levels was 
confirmed in a recent study of 22 pregnant women treated with anti-thyroid medication 
(Fig. 10; Vanmiddlesworth et al., 2011). A significant increase in maternal compound W was 
observed when the PTU dose was decreased or discontinued.  
 
Fig. 10. Courses of compound W in serum of pregnant patients with hyperthyroidism 
receiving antithyroid therapy. Two or more points on dotted lines mark the course of 
compound W in each patient, and the thick continuous black line shows the marginal mean 
course. Thick gray lines represent the 10th (lower) and 90th (upper) percentiles. Square 
markers on solid lines indicate suppressed or nonprogressive serial measurements in 5 
patients; triangular markers on solid lines denote 2 patients who had transient progression 
and then reduction below the 10th percentile at term.  
Cortelazzi, et al. (Cortelazzi et al., 1999) suggest that abnormal thyroid function will be 
revealed by an absence of the normal rise of compound W during gestation. In 
comparison with relatively low incidence of congenital hypothyroidism in this population 
(Rastogi & LaFranchi, 2010; Harris & Pass, 2007), serial measurements of compound W in 
maternal serum can be considered a safe and practical test for the assessment of fetal 
thyroid function, particularly in hyperthyroid women treated with anti-thyroid drugs, 
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whose fetuses can become hypothyroid due to the transplacental passage of the drug (Fig. 
10; Vanmiddlesworth et al., 2011).  
Further study is needed to include compound W levels in a greater number of hyperthyroid 
pregnant women treated with anti-thyroid medication or pregnant women with evidence of 
autoimmune thyroid illnesses, followed by long-term follow-up of psychomotor 
development in these seemingly euthyroid babies. Suppressed W levels may help to define 
the sub-group of children exposed to PTU in utero or born to mothers with autoimmune 
disease who have been shown to have an adverse cognitive outcome (Grasberger & Refetoff, 
2011; Rovet et al., 1999; Mirabella et al., 2000; Mitchell & Klein, 2004; Casey et al., 2005). 
7. Conclusion 
Sulfoconjugation is a major metabolic pathway for thyroid hormone in developing 
mammals. The significant rise of sulfated iodothyronines in mammalian fetal compartments 
raises the possibility that significant fetal to maternal transfer of the conjugates may occur in 
late gestation as the fetal hypothalamic-pituitary-thyroid system becomes more mature. This 
transfer may be a novel mechanism to maintain low T3 states or regulate serum T2, a 
thermogenic hormone that is important for normal tissue maturity. The possibility that the 
transferred iodothyronine sulfate, especially T2S and its metabolite, may serve as a marker 
of fetal thyroid function needs to be further explored. 
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